---
figid: PMC6628314__cancers-11-00737-g001
figlink: /pmc/articles/PMC6628314/figure/cancers-11-00737-f001/
number: Figure 1
caption: Schematic representation of members of the human epidermal growth factor
  receptor (HER) family, their natural ligands, interaction with the HER2-targeted
  therapies trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), lapatinib, and
  neratinib, and the downstream consequences of these interactions. Circles on EGFR,
  HER2, and HER4 represent the active kinase domain; the kinase domain on HER3 is
  inactive. Ligand binding initiates homo- or heterodimerization of HER family members,
  leading to intracellular signaling cascades that are dependent on the dimers formed
  (e.g., PI3K/AKT and MAPK [Ras/MEK/extracellular signal-regulated kinase (ERK)]).
  HER-family signaling affects multiple cell processes including cell cycle, metabolism/protein
  synthesis, proliferation, migration, epithelial–mesenchymal transition (EMT), and
  apoptosis. Trastuzumab inhibits HER2 signaling and can engage in antibody-dependent
  cell-mediated cytotoxicity (ADCC). Pertuzumab can also mediate ADCC and inhibits
  HER2 dimer formation, abrogating HER2 intracellular signaling. The trastuzumab-based
  antibody–drug conjugate T-DM1 maintains the functions of trastuzumab but also delivers
  a cytotoxic payload (emtansine) on internalization of the receptor/T-DM1 complex.
  Lapatinib and neratinib are small-molecule tyrosine kinase inhibitors targeting
  the cytoplasmic ATPase domain of HER family members. This figure is adapted from
  publications by Roskoski et al. [], Segovia-Mendoza et al. [], Kourie et al. [],
  Appert-Collin et al. [] and references cited therein; further detail can be found
  within those publications. Signaling pathway interactions adapted from the KEGG
  pathway database. AKT, protein kinase B; EGF, epidermal growth factor; EGFR, epidermal
  growth factor receptor; ERK, extracellular signal-regulated kinase; HB-EGF, heparin-binding
  EGF-like growth factor; JAK, Janus kinase; MEK, mitogen-activated protein kinase
  kinase; NRG, neuregulin; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C;
  PLCγ, phospholipase C-γ; PTEN, phosphatase and tensin homolog; STAT, signal transducer
  and activator of transcription; TGF, transforming growth factor.
pmcid: PMC6628314
papertitle: 'Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor
  Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive
  and HER2-Mutated Breast Cancer.'
reftext: Denis M. Collins, et al. Cancers (Basel). 2019 Jun;11(6):737.
pmc_ranked_result_index: '30351'
pathway_score: 0.8807147
filename: cancers-11-00737-g001.jpg
figtitle: 'Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor
  Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive
  and HER2-Mutated Breast Cancer.'
year: '2019'
organisms: Homo sapiens
ndex: 9d9471c1-df15-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6628314__cancers-11-00737-g001.html
  '@type': Dataset
  description: Schematic representation of members of the human epidermal growth factor
    receptor (HER) family, their natural ligands, interaction with the HER2-targeted
    therapies trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), lapatinib, and
    neratinib, and the downstream consequences of these interactions. Circles on EGFR,
    HER2, and HER4 represent the active kinase domain; the kinase domain on HER3 is
    inactive. Ligand binding initiates homo- or heterodimerization of HER family members,
    leading to intracellular signaling cascades that are dependent on the dimers formed
    (e.g., PI3K/AKT and MAPK [Ras/MEK/extracellular signal-regulated kinase (ERK)]).
    HER-family signaling affects multiple cell processes including cell cycle, metabolism/protein
    synthesis, proliferation, migration, epithelial–mesenchymal transition (EMT),
    and apoptosis. Trastuzumab inhibits HER2 signaling and can engage in antibody-dependent
    cell-mediated cytotoxicity (ADCC). Pertuzumab can also mediate ADCC and inhibits
    HER2 dimer formation, abrogating HER2 intracellular signaling. The trastuzumab-based
    antibody–drug conjugate T-DM1 maintains the functions of trastuzumab but also
    delivers a cytotoxic payload (emtansine) on internalization of the receptor/T-DM1
    complex. Lapatinib and neratinib are small-molecule tyrosine kinase inhibitors
    targeting the cytoplasmic ATPase domain of HER family members. This figure is
    adapted from publications by Roskoski et al. [], Segovia-Mendoza et al. [], Kourie
    et al. [], Appert-Collin et al. [] and references cited therein; further detail
    can be found within those publications. Signaling pathway interactions adapted
    from the KEGG pathway database. AKT, protein kinase B; EGF, epidermal growth factor;
    EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase;
    HB-EGF, heparin-binding EGF-like growth factor; JAK, Janus kinase; MEK, mitogen-activated
    protein kinase kinase; NRG, neuregulin; PI3K, phosphoinositide 3-kinase; PKC,
    protein kinase C; PLCγ, phospholipase C-γ; PTEN, phosphatase and tensin homolog;
    STAT, signal transducer and activator of transcription; TGF, transforming growth
    factor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - STAT4
  - SRC
  - PRKCG
  - STAT1
  - STAT2
  - PLCG1
  - PTEN
  - PRKCH
  - PRKCI
  - HRAS
  - EPGN
  - AREG
  - BTC
  - TGFA
  - STAT3
  - STAT5A
  - STAT5B
  - PRKCZ
  - PLCG2
  - NRAS
  - KRAS
  - EREG
  - JAK3
  - TYK2
  - MAP2K1
  - MAP2K2
  - NRG1
  - NRG2
  - NRG3
  - NRG4
  - STAT6
  - ERBB3
  - HBEGF
  - EGF
  - PIK3R3
  - PRKCQ
  - PRKD3
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - AKT3
  - AKT1
  - AKT2
  - EGFR
  - ERBB4
  - SLC25A15
  - JAK1
  - JAK2
  - PIK3CD
  - PIK3CG
  - ERBB2
  - MAPK1
  - MAPK3
  - PIK3R4
  - PIK3CA
  - PIK3R6
  - PIK3R5
  - PIK3CB
  - Epigen
  - Lapatinib
  - Neratinib
  - Cancer
  - Lung cancer
genes:
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT4
  entrez: '6775'
- word: SRC
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT2
  entrez: '6773'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: EGFRligands
  symbol: EGFR_ligand
  source: bioentities_symbol
  hgnc_symbol: EPGN
  entrez: '255324'
- word: EGFRligands
  symbol: EGFR_ligand
  source: bioentities_symbol
  hgnc_symbol: AREG
  entrez: '374'
- word: EGFRligands
  symbol: EGFR_ligand
  source: bioentities_symbol
  hgnc_symbol: BTC
  entrez: '685'
- word: EGFRligands
  symbol: EGFR_ligand
  source: bioentities_symbol
  hgnc_symbol: TGFA
  entrez: '7039'
- word: Epigen
  symbol: epigen
  source: hgnc_alias_symbol
  hgnc_symbol: EPGN
  entrez: '255324'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PLCY
  symbol: PLCG
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: EGFRligands
  symbol: EGFR_ligand
  source: bioentities_symbol
  hgnc_symbol: EREG
  entrez: '2069'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: NRG-1
  symbol: NRG1
  source: hgnc_symbol
  hgnc_symbol: NRG1
  entrez: '3084'
- word: NRG-2
  symbol: NRG2
  source: hgnc_symbol
  hgnc_symbol: NRG2
  entrez: '9542'
- word: NRG-3
  symbol: NRG3
  source: hgnc_symbol
  hgnc_symbol: NRG3
  entrez: '10718'
- word: NRG-4
  symbol: NRG4
  source: hgnc_symbol
  hgnc_symbol: NRG4
  entrez: '145957'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT6
  entrez: '6778'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: EGFRligands
  symbol: EGFR_ligand
  source: bioentities_symbol
  hgnc_symbol: HBEGF
  entrez: '1839'
- word: EGFRligands
  symbol: EGFR_ligand
  source: bioentities_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: HER4
  symbol: HER4
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB4
  entrez: '2066'
- word: HHH
  symbol: HHH
  source: hgnc_prev_symbol
  hgnc_symbol: SLC25A15
  entrez: '10166'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: HB-EGF
  symbol: HBEGF
  source: hgnc_symbol
  hgnc_symbol: HBEGF
  entrez: '1839'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
chemicals:
- word: Epigen
  source: MESH
  identifier: D066261
- word: Lapatinib
  source: MESH
  identifier: C490728
- word: Neratinib
  source: MESH
  identifier: C487932
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
